FDA Warning Letter Breakdown: Sterility Failures, Subpotent GLP 1 Drugs, and a Compounding Pharmacy Operating Without Control In 2023, the FDA deemed 19 peptides too unsafe to be dispensed by compounding pharmacies. Now, under RFK Jr., the agency is poised to reverse itself despite the fact that few Content Analysis of US FDA Warning Letters Issued to Compounding Pharmacies Regarding Violations of Current Good Manufacturing Practices Between 2017 and 2022 Journal of Pharmaceutical Innovation Springer Nature Link FDA Moves on Peptides: What Compounding Pharmacies Need to Know